Earnings ·
Lipocine Inc. reported financial results for the quarter ended June 30, 2026, showing a net loss of $2.6 million, or…
LPCNLipocine Inc.
Lipocine Inc. reported financial results for the quarter ended June 30, 2026, showing a net loss of $2.6 million, or ($0.32) per diluted share, compared to a net loss of $2.2 million in the prior year period. Cash and equivalents increased to $23.3 million from $14.9 million at year-end 2025. The company announced that its Phase 3 trial for LPCN 1154 (BRLIZIO) in postpartum depression missed its primary endpoint, though a post hoc analysis excluding an outlier site showed clinically meaningful improvement. Lipocine has requested an FDA guidance meeting scheduled for the third quarter of 2026 and initiated a new Phase 3 trial to complement existing data. Additionally, Pharmalink received marketing authorization for TLANDO in the UAE on July 8, 2026. Lipocine Inc. is a biopharmaceutical company focused on developing novel oral therapeutics.